Primary progressive multiple sclerosis and Raynaud's phenomenon

Summary:

Raynaud's phenomenon is found among people with Primary progressive multiple sclerosis, especially for people who are female, 50-59 old.

The study analyzes which people have Raynaud's phenomenon with Primary progressive multiple sclerosis. It is created by eHealthMe based on reports of 31 people who have Primary progressive multiple sclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Primary progressive multiple sclerosis?

Primary progressive multiple sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged) is found to be associated with 37 drugs and 70 conditions by eHealthMe. Check the latest studies of Primary progressive multiple sclerosis.

What is Raynaud's phenomenon?

Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 628 drugs and 996 conditions by eHealthMe. Check the latest studies of Raynaud's phenomenon.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

31 people who have Primary Progressive Multiple Sclerosis and Raynaud'S Phenomenon are studied.

Would you have Raynaud's phenomenon when you have Primary progressive multiple sclerosis?

Gender of people who have Primary Progressive Multiple Sclerosis and experienced Raynaud'S Phenomenon *:

female: 96.77 %
male: 3.23 %

Age of people who have Primary Progressive Multiple Sclerosis and experienced Raynaud'S Phenomenon *:

Common co-existing conditions for these people *:

Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 24 people, 77.42%
Adverse Event: 2 people, 6.45%
Micturition Urgency (urgency to pass the urine): 1 person, 3.23%
Insomnia (sleeplessness): 1 person, 3.23%
Indigestion: 1 person, 3.23%
Affect Lability (emotional incontinence): 1 person, 3.23%

Common drugs taken by these people *:

Ocrevus: 27 people, 87.10%
Sertraline: 24 people, 77.42%
Ramipril: 17 people, 54.84%
Levothyroxine Sodium: 15 people, 48.39%
Omeprazole: 2 people, 6.45%
Methylprednisolone: 2 people, 6.45%
Ibuprofen: 2 people, 6.45%
Dexamethasone: 2 people, 6.45%
Cetirizine Hydrochloride: 2 people, 6.45%
Acetaminophen: 2 people, 6.45%

Common symptoms for these people *:

Rashes (redness): 27 people, 87.10%
Vestibular Disorder (disorders of the body's balance (vestibular) system in the inner ear): 27 people, 87.10%
Fatigue (feeling of tiredness): 27 people, 87.10%
Urinary Tract Infection: 27 people, 87.10%
High Blood Cholesterol: 27 people, 87.10%
High Blood Pressure: 27 people, 87.10%
Central Nervous System Lesion (an abnormality in tissue of brain or spinal cord): 27 people, 87.10%
Residual Urine Volume Increased (excess destruction or solution of the elements of bone): 27 people, 87.10%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 26 people, 83.87%
Uveitis (inflammation of the uvea): 26 people, 83.87%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Raynaud's phenomenon?

- Check whether Raynaud's phenomenon is associated with a drug or a condition

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Raynaud's phenomenon and Primary progressive multiple sclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.